The Life Sciences team guided Orionis Biosciences on their second multi-year collaboration with Genentech, a member of the Roche Group, to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology. Under the terms of the agreement, Orionis will be responsible for the discovery and optimization of molecular glues using Orionis' Allo-Glue" platform. Genentech will be responsible for subsequent later-stage preclinical and clinical development, regulatory filing, and commercialization of such small molecules. Orionis will receive an upfront payment of $105 million and is eligible for potential research, development, commercial and net sales milestone payments, whose total could exceed $2 billion as well as potential tiered royalties upon sale of collaboration products.
Orionis Biosciences is a clinical-stage life sciences company pioneering the systematic discovery and rational design of therapeutic modalities that invoke molecular proximity-based mechanisms of action to impact challenging and traditionally elusive disease targets. The company's Allo-Glue" platform enables unprecedented target-centric and target-agnostic discovery and design of small molecule glues for any induced proximity applications. Its A-Kine" biologics platform comprises an array of engineered cytokines that exhibit exquisite cell-target selectivity, and novel types of multifunctional immune cell engagers. The company is advancing a deep and diversified pipeline of oncology programs and cancer immunotherapies. It leverages its disruptive technologies across multiple disease targets and therapeutic indications in collaboration with industry partners.
The Goodwin deal team was led by Noelle Dubiansky, Jennifer Ford, Julia Shaver, with valuable assistance provided by William Collins and Daniel Karelitz.
For more information on the deal, please read the press release.